Eli Lilly CDR (CAD Hedged)

Nxera Pharma has launched a broad proprietary pipeline targeting obesity and chronic weight management, led by a new oral small molecule GLP-1 agonist program.

Swiss generic manufacturer Sandoz plans to launch unbranded semaglutide weight-loss drugs in Canada at discounts of up to 70% compared to branded versions once patents expire next year.

Frazier Healthcare Partners has successfully closed a $1.3 billion venture capital fund specifically targeting early-stage biotechnology companies and startup creation.

GSK's anti-TIM-3 monoclonal antibody cobolimab failed to improve overall survival in the Phase III COSTAR trial for advanced non-small cell lung cancer patients previously treated with immunotherapy.

Therini Bio has dosed the first patient in a Phase 1b trial of THN391, a first-in-class monoclonal antibody targeting fibrin-mediated neuroinflammation in Alzheimer's disease.

Roche announced plans to test Trontinemab, an experimental drug designed to delay or prevent Alzheimer's disease symptoms in at-risk individuals.

BioChaperone Lispro (THDB0206) demonstrated non-inferior HbA1c reduction compared to Humalog in a Phase 3 trial of 1,040 Chinese adults with Type 2 diabetes.

Gate Bioscience announced a collaboration and license agreement with Eli Lilly to discover and develop molecular gate therapeutics, a new class of small molecule drugs that eliminate disease-causing proteins at their source.

Roche is considering selling prescription medicines directly to US consumers to lower patient costs, following government pressure to reduce drug prices.

IXICO has deepened its collaboration with the Global Alzheimer's Platform Foundation through an agreement securing full data usage rights to the Bio-Hermes-002 study, one of the most prominent global studies in Alzheimer's disease research.